Developing strategies to overcome prostate stromal- derived NRG1-mediated resistance to AR blockade in high-risk locally advanced prostate cancer

Ended Project Grant Awarded Last action

Award ID
W81XWH2110431
Recipient
Awarding agency
Obligated
$1,327,473

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
New York, NY 10065, USA

Award details come from USAspending.gov.

About this award

The Sloan-Kettering Institute for Cancer Research was awarded a $1,327,473 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420).

The grant will support research efforts from June 2021 through May 2024 to develop strategies for overcoming prostate stromal-derived neuregulin 1-mediated resistance to androgen receptor blockade in high-risk locally advanced prostate cancer. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award will further those goals by investigating approaches to make prostate cancer treatment more effective for service members and civilians facing this disease.

Quick answers

Who received award W81XWH2110431?

W81XWH2110431 was awarded to Sloan-Kettering Institute For Cancer Research by Medical Command (Department of the Army) on June 1, 2021.

How much is award W81XWH2110431 worth?

$1,327,473 has been obligated on W81XWH2110431.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award